Khanji, Cynthia
Schnitzer, Mireille E.
Bareil, Céline
Perreault, Sylvie
Lalonde, Lyne
Funding for this research was provided by:
Pfizer–FRQS–MSSS chronic disease fund (N/A)
Article History
Received: 14 September 2018
Accepted: 13 June 2019
First Online: 3 July 2019
Ethics approval and consent to participate
: The current study is a secondary analysis of the data collected in the cluster randomized controlled trial (Phase III) and has been approved by the research ethics board of the <i>Centre de santé et de services sociaux de Laval</i> (CSSSL) (2013–2014/04–02). Every participating clinician and patient signed an informed consent form.
: Not applicable.
: The following authors report conflicts of interest: In 2015, Cynthia Khanji won a scholarship funded by Pfizer Canada Inc. and <i>Réseau Québécois de recherche sur les medicaments</i> (RQRM) which allowed her to do an internship at Pfizer Canada Inc. during the summer of 2016. She has also been working part-time at Pfizer Canada since December 2016. Lyne Lalonde has conducted research sponsored by Amgen Canada Inc., LEO Pharma Inc. and Pfizer Canada Inc. The other authors report no conflicts of interest.